Characterization and Quantification of Microplastics and Nanoplastics (MNPs) in Human Blood

The Centers for Disease Control and Prevention intends to award a sole-source, firm-fixed-price contract to Columbia University for the characterization and quantification of microplastics and nanoplastics (MNPs) in human blood. This collaborative research initiative involves performing laboratory analyses to validate extraction and measurement protocols and assessing variability in MNP detection using advanced analytical instrumentation. The work integrates agency laboratory expertise with specialized contractor capabilities to establish reliable measurement approaches and improve the scientific understanding of MNP detection within biological matrices.

The anticipated period of performance for this project is September 15, 2026, through September 14, 2028, with primary activities occurring in Atlanta, Georgia. This requirement is classified under NAICS 541380, Testing Laboratories and Services, and PSC R425, Support- Professional: Engineering/Technical. There is no set-aside associated with this action, which is being conducted under the authority of FAR 12.102 and 41 U.S.C. 1901 and 1903.

While the government intends to negotiate with only one source, interested parties may identify their interest and capability or submit proposals for consideration. All responses received by 3:00 PM ET on June 19, 2026, under solicitation number 000HCNBC-2026-99178, will be used to determine whether to conduct a competitive procurement. The government maintains sole discretion in determining whether to compete the contract based on information received from this pre-solicitation notice.